We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

LIM Kinase (LIMK)

LIM kinase (LIMK) inhibitors target LIMK1 and LIMK2, two protein kinases that regulate actin filaments. The LIM name comes from a zinc-binding domain first found in the proteins Lin-11, Isl-1 and Mec-3. In 1998 two groups showed that LIMK1 phosphorylates cofilin and so inactivates this actin-depolymerizing factor. Phosphorylated cofilin no longer severs filaments, and filamentous actin accumulates. Upstream, Rho-associated protein kinase (ROCK) activates LIMK1 by phosphorylating threonine 508 in its activation loop. LIMK inhibitors are used to study cell migration, invasion and neuronal morphology. BMS-5 and BMS-3 inhibit both isoforms, while T56-LIMKi and LX7101 are listed as LIMK2 inhibitors. TH-257 and TH-263 are further LIMK inhibitors listed in this category.

3 Items

  • DB0614
    Cat. No.
    A24447
    CAS No.
    2769753-47-9

    DB0614

    DB0614 is a PROTAC molecule utilizing a cereblon ligand, designed as a selective and potent degrader of NEK9 and other kinases. It induces the degradation of multiple kinases, including ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1–3, MAP4K5, MAPK14, MAPK7–9, MAPKAPK2/3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1/3, SIK2/3, STK35, TNK2, and ULK1. DB0614 is suitable for research involving diseases or disorders driven by aberrant kinase activity.

    In stock View Details
    1 mg
    $180.00
    5 mg
    $540.00
    All 4 sizes
  • DD-03-156
    Cat. No.
    A24496
    CAS No.
    2769753-69-5

    DD-03-156

    Synonyms: (S,R,S)-AHPC-Me-PEG2-dabrafenib

    DD-03-156 is a potent and selective degrader of CDK17 and LIMK2. It exhibits high selectivity and potency, making it a strong candidate for the development of a chemical probe targeting CDK17 degradation.

    In stock View Details
    5 mg
    $252.00
    10 mg
    $434.00
    All 4 sizes
  • DB1113
    Cat. No.
    A24837
    CAS No.
    2769753-53-7

    DB1113

    DB1113 is a bifunctional compound designed for targeted protein degradation of various kinases. It effectively induces degradation of ABL1, ABL2, BLK, CDK4, CDK11B, EPHA3, MAPK7, RIPK1, and others, facilitating the investigation of kinase-related signaling pathways. DB1113 is suitable for research focusing on diseases or disorders associated with dysregulated kinase activity, providing a valuable tool for exploring therapeutic interventions in cancer and other conditions.

    In stock View Details
    5 mg
    $695.00
    10 mg
    $1,220.00
    All 2 sizes

3 Items

Added to your cart

View Cart Checkout

    Loading...